Phase III Study Results of Pembrolizumab Plus Chemotherapy in SCLC to be Presented at ASCO

Posted on

In a double-blind, phase III study of pembrolizumab in combination with etoposide and platinum (EP)-based chemotherapy versus placebo and EP as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC), treatment with pembrolizumab plus EP therapy was found to improve progression free survival and prolong overall survival, according to data that will be presented at the 2020 ASCO Virtual Scientific Program.

The program will be held May 29-31.

Full abstract can be found here.

Abstract #9001, Oral Abstract Session: KEYNOTE-604: Pembrolizumab (pembro) or Placebo plus Etoposide and Platinum (EP) as First-Line Therapy for Extensive-Stage (ES) Small-Cell Lung Cancer (SCLC). C. Rudin. Sunday, May 31, 10-10:30 a.m. ET.